CompanyDrug

CF PharmTech Wins NMPA Approval for Olopatadine Mometasone Combo Trial – Fixed-Dose Nasal Spray Targets Moderate-to-Severe Allergic Rhinitis

Fineline Cube
By
Fineline Cube
3 Min Read
Summarize with AI

CF PharmTech Inc. (HKG: 2652) announced NMPA clearance to initiate a clinical study for its fixed-dose combination of olopatadine (antihistamine) and mometasone (corticosteroid) for the treatment of moderate-to-severe allergic rhinitis in adults and adolescents aged 12 years and older. The single-formulation nasal spray addresses unmet needs in the respiratory allergy market by combining dual mechanisms for enhanced symptom control and improved patient adherence.

Contents
- Advertisement -

Regulatory Milestone

ItemDetail
AgencyNMPA (China)
Approval TypeClinical trial authorization (IND)
ProductOlopatadine + mometasone fixed-dose combination
FormulationNasal spray (single-device)
IndicationModerate-to-severe allergic rhinitis
Target PopulationAdults and adolescents ≥12 years
DeveloperCF PharmTech Inc. (Wuxi, China)
Approval DateMarch 2026

Product Profile & Mechanism

ComponentClassMechanismContribution
OlopatadineH1-antihistamine (selective, non-sedating)Blocks histamine H1 receptors; mast cell stabilizationRapid relief of nasal itching, sneezing, rhinorrhea
MometasoneIntranasal corticosteroid (potent, low bioavailability)Anti-inflammatory; reduces nasal mucosa inflammationSustained control of nasal congestion, overall symptom severity

Combination Rationale:

  • Dual pathway blockade: Antihistamine addresses immediate hypersensitivity; corticosteroid targets underlying inflammation
  • Convenience advantage: Single nasal device vs. separate antihistamine and steroid sprays (improved adherence)
  • Efficacy synergy: Fixed-dose timing optimizes pharmacodynamic coordination

Market Context & Competitive Landscape

FactorStrategic Implication
Allergic Rhinitis Burden400+ million affected in China; moderate-to-severe represents 30-40% of diagnosed patients
Standard of CareIntranasal corticosteroids (fluticasone, mometasone) first-line; antihistamines adjunctive
Combination GapNo fixed-dose antihistamine/corticosteroid nasal sprays approved in China; patients use separate devices
Adherence ChallengeComplex multi-spray regimens reduce compliance; simplified single-device improves outcomes
Competitive ThreatsGeneric mometasone flooding market; olopatadine differentiation via combination patent protection

Development Outlook

PhaseTimelineObjectives
Phase I2026Safety, tolerability, pharmacokinetics of combination formulation
Phase II2027-2028Dose-ranging, efficacy vs. monotherapy components
Phase III2028-2029Non-inferiority/superiority vs. free-combination standard of care
NDA Filing2029-2030China approval as first fixed-dose nasal spray for allergic rhinitis

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for CF PharmTech’s olopatadine/mometasone combination. Actual results may differ due to formulation challenges, competitive dynamics, and reimbursement decisions in the respiratory allergy market.-Fineline Info & Tech

2026030900030_cDownload
TAGGED:
Share This Article
Previous Article Dongcheng Pharma Doses First Patient in 225Ac-LNC1011 Phase I/II Trial – PSMA-Targeted Alpha Radiotherapy for Metastatic Prostate Cancer
Next Article Haisco’s HSK39297 NMPA Filing Accepted – Oral Factor B Inhibitor Targets Paroxysmal Nocturnal Hemoglobinuria Market

You May also Like

CompanyDeals

Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline

CompanyDrug

Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment

Eli Lilly's Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity
CompanyDrug

Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity

CompanyDrug

Huadong Medicine’s EGFR Inhibitor Mefatinib for NSCLC Accepted by NMPA for Review

Show More